Seattle Genetics Inc. CEO Clay Siegall envisions a broader collaboration with Bristol-Myers Squibb Co. on blood cancer combinations following the release of encouraging data for the anti-CD30 antibody-drug conjugate Adcetris and the PD-1 inhibitor Opdivo in relapsed Hodgkin lymphoma.
Adcetris (brentuximab vedotin), which is partnered with Takeda Pharmaceutical Co. Ltd., is approved for classical Hodgkin lymphoma after the...